Aims: Gastric cancer (GC) is one of the leading causes of cancer-related death worldwide. Genes expressed only in cancer tissue may be useful biomarkers for cancer diagnosis and therapeutics. The aims of the present study were to analyse regulator of calcineurin 2 (RCAN2) in a large number of GCs, and to investigate how these expression patterns correlate with clinicopathological parameters and various markers. Methods and results: An immunohistochemical analysis of RCAN2 in 207 GC tissue samples showed that 110 (53%) GCs were positive for RCAN2. RCAN2-positive GCs were more advanced in terms of TNM classification and tumour stage than RCAN2-negative GCs. Furthermore, RCAN2 was an independent prognostic classifier for GC patients. The cell growth and invasiveness of RCAN2 small interfering RNA (siRNA)-transfected GC cell lines were less than those of the negative control siRNA-transfected cell lines, whereas those of RCAN2-transfected cells were significantly increased as compared with those of empty vector-transfected cells. RCAN2 siRNA inhibits the phosphorylation of AKT and p44/p42 (ERK1/2). RCAN2 was colocalised with EGFR, nuclear b-catenin, MMP7, laminin-c2, VEGF-A, and VEGF-C. Conclusion: These results suggest that RCAN2 is involved in tumour progression and is an independent prognostic classifier in patients with GC.
Introduction
Gastric cancer (GC), which is one of the most common malignancies worldwide, develops as a result of multiple genetic and epigenetic alterations. 1 Advances in diagnostics and treatments have led to excellent longterm survival for patients with GC that is detected early. 2 However, despite these improvements, the prognosis of advanced GC with extensive invasion and metastasis remains poor. Several discrete steps can be discerned in the biological cascades of invasion and metastasis, 3 and the involvement of several molecules in mediating GC aggressiveness has been suggested. 4 Regulator of calcineurin (RCAN) proteins are important endogenous modulators that interact with calcineurin and alter its function by interfering with calcineurin-cytosolic nuclear factor of activated T cells (NFATc) binding, among other things. The calcineurin-NFATc signalling pathway is crucial in several biological processes, such as lymphocyte activation, angiogenesis, morphogenesis of the heart valves, and neural and muscle development. 5, 6 RCAN proteins are involved in the development of several pathological conditions, such as Down's syndrome, cardiac hypertrophy, and Alzheimer's disease. [7] [8] [9] RCAN2 (also known as ZAKI-4, Dscr1/1, MCIP2, and Calcipressin2) was originally identified as a thyroid hormone (T3)-responsive gene in cultured human skin fibroblasts, 10 and was subsequently reported to function as a calcineurin regulator. 11, 12 Evidence of altered RCAN proteins in various human malignancies has been accumulating, and several studies have reported the inhibitory and facilitative effects of RCAN proteins on cancer cell growth. [13] [14] [15] [16] Our previous study clarified that KRAS mutations in colorectal cancer (CRC) lead to decreased RCAN2 expression, resulting in tumour proliferation because of derepression of the calcineurinNFATc signalling pathway. 17 To date, RCAN proteins, including RCAN2, have not been investigated in GC.
The present study represents the first detailed analysis of RCAN2 in GC, including its clinicopathological significance and biological function. To clarify the pattern of expression and localisation of RCAN2 in GC, we performed immunohistochemical analysis of surgically resected GC samples, and investigated the association between RCAN2 and various markers involving GC.
Materials and methods

E T H I C S S T A T E M E N T
All patient samples were obtained with consent, and this study was approved by the Ethics Committee for Human Genome Research of Hiroshima University (26 January 2017, approval No. IRINHI 66) and conformed to the ethical guidelines of the Declaration of Helsinki.
In this retrospective study, 207 primary tumours were collected from patients diagnosed as having GC who underwent curative resection at Hiroshima University Hospital (Hiroshima, Japan). Only patients without preoperative radiotherapy or chemotherapy were enrolled in the study. The study population included 125 men and 82 women. Postoperative follow-up was scheduled every 1, 2 or 3 months during the first two postoperative years and every 6 months thereafter, unless more frequent follow-up was deemed to be necessary. Chest X-rays, chest computed tomography scans and serum chemistry analyses were performed at every follow-up visit. Recurrence was evaluated from the Hiroshima University Hospital records. Archival formalin-fixed paraffin-embedded tissues from the 207 patients were used for immunohistochemical analysis. The histological classifications were determined according to the World Health Organisation system. Tumour staging was performed according to the TNM staging system.
We immunohistochemically examined the expression of p53, epidermal growth factor receptor (EGFR), b-catenin, matrix metalloproteinase 7 (MMP7), laminin-c2, vascular endothelial growth factor (VEGF)-A and VEGF-C by using a tissue microarray analysis of 682 GCs. Human GC-derived cell lines, i.e. MKN1, MKN7, MKN45, MKN74,and TMK1, were purchased from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan). All cell lines were maintained in RPMI-1640 (Nissui Pharmaceutical, Tokyo, Japan) containing 10% fetal bovine serum (Whittaker, Walkersville, MD, USA) in a humidified atmosphere of 5% CO 2 /95% air at 37°C.
I M M U N O H I S T O C H E M I S T R Y
One or two representative tumour blocks, including the tumour centre and invasive front, from each patient were examined immunohistochemically. For large, late-stage tumours, two different sections were examined to include representative areas of both the tumour centre and the lateral and deep tumour invasive fronts. The immunohistochemical analysis was performed with a Dako Envision+ Mouse/rabbit Peroxidase Detection System (Dako Cytomation, Carpinteria, CA, USA). Antigen retrieval was performed by microwave heating in citrate buffer (pH 6.0) for 30 min. Peroxidase activity was blocked with 3% H 2 O 2 /methanol for 10 min, and the sections were incubated with normal goat serum (Dako Cytomation) for 20 min to block non-specific antibody-binding sites. Sections were then incubated with a rabbit polyclonal anti-RCAN2 antibody (Thermo Scientific, Rockford, IL, USA; diluted 1:500) for 1 h at room temperature, and then with Envision+ antimouse peroxidase for 1 h. The anti-RCAN2 antibody recognised both isoform 1 and isoform 2 of human RCAN2. Sections were incubated with DAB Substrate-Chromogen Solution (Dako Cytomation) for 10 min to produce a colour reaction. Sections were then counterstained with 0.1% haematoxylin. Negative controls were created by omission of the primary antibody.
RCAN2 in GC was scored in all tumours as positive or negative. When >10% of tumour cells were stained, immunostaining was considered to be positive for RCAN2. The expression of p53, EGFR, nuclear b-catenin, MMP7, laminin-c2, VEGF-A and VEGF-C at the invasive front was scored in all tumours as positive or negative. When >10% of tumour cells were stained, the immunostaining was considered to be positive for each molecule. Using these definitions, two surgical pathologists (Y.H. and K.S.), without knowledge of the clinical or pathological parameters or of the patients' outcomes, independently reviewed the immunoreactivity of each specimen. Interobserver differences were resolved by consensus review at a double-headed microscope after independent review.
R N A I N T E R F E R E N C E ( R N A I )
To knock down endogenous RCAN2, RNAi was performed as described previously. 18 Small interfering RNA (siRNA) oligonucleotides for RCAN2 and a negative control were purchased from Invitrogen (Carlsbad, CA, USA). Transfection was performed with Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's protocol. Briefly, 60 pmol of siRNA and 10 ll of Lipofectamine RNAiMAX were mixed in 1 ml of RPMI medium (10 nmol/l final siRNA concentration). After 20 min of incubation, the mixture was added to the cells, and these were plated on dishes for each assay. The cells were analysed in all experiments at 48 h after transfection.
L E N T I V I R A L A N D R E T R O V I R A L V E C T O R S
RCAN2 was amplified from MKN1 cDNA by polymerase chain reaction (PCR). The PCR fragment was ligated into a pDON-5 Neo plasmid (3655; Takara, Kusatsu, Japan) at the BamHI sites. All of the above were cloned into the lentiviral transfer vector pTRIPZ (RHS4740-EG11199; GE Healthcare, Little Chalfont, UK) and were verified by sequencing. A lentivirus was produced by cotransfecting the transfer vector containing the gene of interest, the VSVG envelope glycoprotein and the lentiviral packaging vector into HEK293T cells (#HCL4517; Dharmacon, Lafayette, CO, USA). The virus supernatant was concentrated by ultrafiltration with Millex-HV (Millipore, Burlington, MA, USA). In parallel, transduced cells were selected in medium containing 3.0 lg/ml puromycin (P7255; Sigma-Aldrich Merck KGaA, St. Louis, MO, USA) or 250 lg/ml G418 (11811031; Life Technologies, Carlsbad, CA, USA), for a time corresponding to the minimum time taken for untransduced cells to completely die in the selection media. Knockdown or overproduction was verified by quantitative reverse transcription PCR (qRT-PCR) analysis and immunohistochemistry.
C E L L G R O W T H A N D I N -V I T R O I N V A S I O N A S S A Y S
A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed to examine cell growth. The cells were seeded at a density of 4000 cells per well in 96-well plates. Cell growth was monitored after 1, 2, and 4 days. Modified Boyden chamber assays were performed to evaluate invasiveness. The cells were plated at 10 000 cells per well in RPMI-1640 medium plus 1% serum in the upper chamber of a Transwell insert (pre-diameter, 8 mm; Chemicon, Temecula, CA, USA) coated with Matrigel. Medium containing 10% serum was placed in the bottom chamber. After 1 and 2 days, the cells in the upper chamber were removed by scraping, and those remaining on the lower surface of the insert were stained with CyQuant GR dye to assess the cell number. We performed three different experiments, and calculated the mean and standard deviation in each of the MTT and modified Boyden chamber assays.
W E S T E R N B L O T T I N G
Tumour cells were lysed for western blotting as described previously. 19 The lysates (40 lg of protein) were solubilised in Laemmli sample buffer (catalogue no. S3401; Sigma-Aldrich Merck KGaA, St. Louis, MO, USA) by boiling, and then subjected to 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis; this was followed by electrotransfer onto a nitrocellulose membrane. Anti-AKT, anti-phospho-AKT, p44/p42 [extracellular signal-regulated kinase (ERK) 1/2] and anti-phospho-p44/p42 (ERK1/2) monoclonal antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-RCAN2 polyclonal antibody was purchased from Novus Biologicals (Littleton, CO, USA). Anti-NFATc3 and anti-phospho-NFATc3 monoclonal antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Peroxidase-conjugated anti-mouse IgG and anti-rabbit IgG were used in the secondary reaction.
Immunocomplexes were visualised with an ECL Western Blot Detection System (Amersham Biosciences, Little Chalfont, UK). b-Actin antibody (Sigma Chemical, St Louis, MO, USA) was also used as a loading control.
Q R T -P C R A N A L Y S I S
Total RNA was extracted with an RNeasy Mini kit (Qiagen, Valencia, CA, USA), and 1 lg of total RNA was converted to complementary DNA (cDNA) by use of a First Strand cDNA Synthesis kit (GE Healthcare Life Sciences, Chalfont, UK). Quantification of BST2 mRNA levels was performed by quantitative fluorescence detection as described previously. 20 PCR was conducted with an SYBR-Green PCR Core Reagents kit (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA). Real-time detection of the emission intensity of SYBR Green bound to double-stranded DNA was performed with the ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Thermo Fisher Scientific). b-Actin-specific PCR products were amplified from the same RNA samples, and served as an internal control. Quantification of ACTB mRNA levels was performed by quantitative fluorescence detection as described previously. 20 qRT-PCR reactions were performed in triplicate for each sample primer set, and the mean of the three experiments was used as the relative quantification value. 21 Primer sequences for RCAN2 were: forward, 5 0 -AAA GCT CTA CTT TGC ACA GGT TC-3 0 ; and reverse, 5
0 -AAG GGG GCG AGA TGA GAA AC-3 0 . Primer sequences for ACTB were: forward, 5 0 -TCA CCG A GC GCG GCT-3 0 ; and reverse, 5 0 -TAA TGT CAC G CA CGA TTT CCC-3 0 . The thermocycling conditions were as described previously.
S T A T I S T I C A L A N A L Y S I S
Correlations between the clinicopathological parameters and RCAN2 were analysed with the v 2 test. Kaplan-Meier survival curves were constructed for RCAN2-positive and RCAN2-negative patients, and survival rates of the two groups were compared. Differences between the survival curves were tested for statistical significance with the log-rank test. Univariate and multivariate Cox regression analyses were used to evaluate the associations between clinical covariates and survival. SPSS (SPSS, Chicago, IL, USA) was used for all statistical analyses. The hazard ratio and 95% confidence interval were estimated from Cox proportional hazard models. Age was treated as a categorical variable (>65 years versus ≤65 years). All variables found to be moderately associated (P < 0.10) with survival in a univariate analysis were included in the final multivariate Cox regression models. P-values of <0.05 were considered to indicate statistical significance.
Results
P R O T E I N A M O U N T A N D D I S T R I B U T I O N O F R C A N 2 I N G C A N D I T S R E L A T I O N S H I P W I T H C L I N I C O P A T H O L O G I C A L P A R A M E T E R S
RCAN2 was immunohistochemically investigated in 207 human GC samples. Staining of RCAN2 in the non-neoplastic gastric mucosa was either weak or absent in epithelial and stromal cells, whereas corresponding GC tissue showed stronger and more extensive staining ( Figure 1A-D) . RCAN2 staining was observed in the cytoplasm of tumour cells (Figure 1C,D) . Of the 207 GC cases, 110 (53%) were positive for RCAN2. The cancer cells robustly expressing RCAN2 were preferentially located in the deeper invasive region of the tumours ( Figure 1A) . Next, we analysed the relationship between RCAN2 amount and various clinicopathological characteristics. RCAN2-positive GCs showed more advanced T stage (P < 0.0001), N stage (P < 0.0001), M stage (P = 0.0002) and tumour stage (P < 0.0001) than RCAN2-negative GCs (Table 1) , in the whole tumour, especially at the invasive front. RCAN2 was also significantly associated with Helicobacter pylori infection (P = 0.0023) but was not associated with age, sex, or histology (Table 1) .
R E L A T I O N S H I P B E T W E E N R C A N 2 I N G C A N D P R O G N O S I S
Kaplan-Meier analysis was performed to investigate the association between RCAN2 and prognosis, to further elucidate the clinical impact of RCAN2 on GC in our 207 patients. RCAN2 amount was significantly associated with a poorer prognosis (P < 0.0001, logrank test; Figure 1E ). The association between RCAN2 amount and survival in GC patients was further evaluated with univariate and multivariate Cox proportional hazards analyses (n = 207; Table 2 ). In the univariate analysis, RCAN2 amount, TNM classification and tumour stage were found to be associated with survival. A multivariate analysis using a model that included RCAN2 amount, TNM classification and tumour stage showed RCAN2 amount, TNM classification and tumour stage to be independent prognostic predictors for survival in GC patients (Table 2 ).
C O R R E L A T I O N O F R C A N 2 W I T H O T H E R M O L E C U L E S
We found that RCAN2 could contribute to tumour progression in GC and that RCAN2 was localised across the whole tumour, especially at the invasive front of GC. The relationship between RCAN2 and GC-related major molecules, including EGFR (Figure 2 ), p53 (Figure 2) , nuclear b-catenin (Figure 2 ), MMP7 (Figure 2) , laminin-c2 (Figure 2 ), VEGF-A ( Figure 3B ), and VEGF-C ( Figure 3C ), was investigated with a tissue microarray analysis of 682 GCs. RCAN2 was colocalised with EGFR (P < 0.0001), nuclear b-catenin (P = 0.0014), MMP7 (P < 0.0001), laminin-c2 expression (P < 0.0001), VEGF-A expression (P < 0.0001) and VEGF-C (P < 0.0001) expression at the invasive front (Table 3) . Several studies have shown that NFATc3, a member of the NFATc family, is a major NFATc species expressed in GC cells. 22, 23 The relationship between RCAN2 and NFATc3 ( Figure 2 ) was investigated with a tissue microarray analysis of 324 GCs. RCAN2 was colocalised with NFATc3 (P < 0.0001).
E F F E C T O F R C A N 2 I N H I B I T I O N O N C E L L G R O W T H A N D I N V A S I V E A C T I V I T Y O F G C C E L L S
Biological studies of RCAN2 were performed with GC cell lines. qRT-PCR revealed MKN1 cells with relatively high endogenous RCAN2 mRNA levels ( Figure 4A ). In MKN1 cells transfected with RCAN2-specific siRNAs (siRNA1, siRNA2, and siRNA3), efficient knockdown of RCAN2 was confirmed ( Figure 4B ). Using MKN1 cells transfected with RCAN2-specific siRNAs (siRNA1, siRNA2, and siRNA3) and MKN1 cells transfected with pDON-RCAN2, we confirmed that RCAN1 mRNA levels were not changed ( Figure S1A,B) . We also confirmed that higher RCAN2 mRNA levels implied an increase in protein levels by using cell immunostaining with pDON-RCAN2-transfected cells and anti-RCAN2 antibody ( Figure S1C ), and by western blotting with GC cell lines, i.e. MKN1 cells transfected with RCAN2-specific siRNAs, and MKN45 cells transfected with RCAN2 vector or empty vector ( Figures 6B and S2) . To investigate the possible antiproliferative effects of RCAN2 knockdown, we performed an MTT assay at 4 days after the transfection with siRNA. The cell growth of the RCAN2 siRNA1-transfected, siRNA2-transfected and siRNA3-transfected MKN1 cells was significantly reduced in comparison with a negative control consisting of siRNA-transfected MKN1 cells ( Figure 4C ). Next, a Transwell invasion assay was performed to determine the possible role of RCAN2 in the invasiveness of GC cells. On day 2, the invasiveness of MKN1 cells with RCAN2 knockdown was <30% of that of the negative control of siRNA-transfected MKN1 cells ( Figure 4D ). Figure 4 . Effects of the inhibition of regulator of calcineurin 2 (RCAN2) on cell growth and invasive activity in gastric cancer (GC) cells. A, MKN1 cells show relatively high endogenous RCAN2 mRNA levels. B, In MKN1 cells transfected with RCAN2-specific siRNAs (siRNA1, siRNA2, and siRNA3), efficient knockdown of RCAN2 was confirmed by quantitative reverse transcription polymerase chain reaction analysis. C, Effect of RCAN2 knockdown on the growth of MKN1 cells. Cell growth was assessed with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay at 1 day, 2 days and 4 days after seeding on 96-well plates. D, The effect of knockdown of RCAN2 on cell invasion in MKN1 cells transfected with RCAN2 siRNA (siRNA1, siRNA2 and siRNA3) or negative control siRNA that were incubated in Boyden chambers. The invading cells were counted after 1 day and 2 days. All experiments shown were repeated three times. Error bars represent standard errors. NS, not significant.
E F F E C T O F R C A N 2 I N H I B I T I O N O N P H O S P H O R Y L A T I O N O F
EGFR activates the Ras-mitogen-activated protein kinase kinase-ERK and AKT-phosphatidylinositol-4,5-bisphosphate 3-kinase signalling pathways, thus leading to cancer cell proliferation and survival. 24 To investigate the RCAN2-induced activation of EGFR signalling in GC, we analysed the phosphorylation of AKT and ERK in GC cells with RCAN2 inhibition. The levels of phosphorylated AKT and ERK were lower in RCAN2 siRNA1-transfected, siRNA2-transfected and siRNA3-transfected MKN1 cells than in control cells ( Figure 5 ). These data suggest that RCAN2 could contribute to tumour progression in GC. To determine the RCAN2-induced activation of NFATc signalling in GC, we analysed the phosphorylation of NFATc3 in GC cells with RCAN2 inhibition. The levels of phosphorylated NFATc3 were lower in RCAN2 siRNA1-transfected, siRNA2-transfected and siRNA3-transfected MKN1 cells than in control cells ( Figure 5 ). These data suggest that RCAN2 is correlated with the NFATc3 phosphorylation level in GC.
To further investigate the function of RCAN2 in GC, MKN45 cells were stably transfected with pDON-RCAN2. Clones were selected in G418 and examined for RCAN2 mRNA expression levels by qRT-PCR. Gene expression analysis and western blotting in MKN45 cells transfected with RCAN2 (MKN45-RCAN2) showed significantly higher levels than in MKN45 cells transfected with empty vector (Figure 6A,B) . To investigate the effect of RCAN2 on cell growth and invasive activity, we performed cell growth and invasion assays on these cells. The cell growth and invasive activity of pDON-RCAN2-transfected cells were significantly increased as compared with those of empty vector-transfected cells ( Figure 6B,C) . These results suggest that RCAN2 stimulates cell growth and invasive activity in GC cells.
Discussion
We previously reported that KRAS mutations in CRC lead to a decrease in RCAN2 expression, resulting in tumour proliferation caused by derepression of calcineurin-NFATc signalling. 17 In the present study, we analysed RCAN2 mRNA and RCAN2 levels and biological functions in GC. RCAN2 was more frequently positive in GC cells than in non-neoplastic gastric mucosa, and 53% of GCs were immunohistochemically positive for RCAN2. The clinicopathological analysis also showed significant associations between RCAN2 and high stage and TNM stages. RCAN2 also served as an independent prognostic classifier of patients with GC. Functional analysis revealed that RCAN2 participated in cell invasion and tumour progression in GC. Taken together, these results indicated that RCAN2 probably plays an important role in tumour progression and poor prognosis in GC. RCAN2 also acts to restrain VEGF-mediated angiogenesis and to inhibit calcineurin activity. 25 However, the relationship between RCAN2 and VEGF remains unclear. RCAN2 could favour NFATc3 phosphorylation by interfering with calcineurin-NFATc binding in GC. However, RCAN2 was colocalised with NFATc3. NFATc3 might be regulated not only by RCAN2 but also by other molecules. Moreover, RCAN2 was significantly colocalised with VEGF-A and VEGF-C (Figure 3 ), and also with EGFR, nuclear b-catenin, MMP7, and cytoplasmic laminin-c2. The levels of phosphorylated AKT and ERK were lower in RCAN2 siRNA-transfected MKN1 GC cells than in control cells. Although the underlying mechanisms remained unclear, we showed that the levels of phosphorylated ERK and AKT were lower in RCAN2 siRNA-transfected GC cells than in control cells. A previous study showed that phosphorylation of ERK and AKT results in inhibition of apoptosis. 26 Thus, apoptosis might also be inhibited in RCAN2 siRNA-transfected GC cells. These results suggested that RCAN2 could be involved in tumour progression, including cell growth and invasion of GC cells, via several growth factors. The present results raise the possibility that RCAN2 might have a dual inhibitory/facilitative role in cancer. The difference in RCAN2 between CRC and GC requires further investigation. Although still unclear, one of the major differences between CRC and GC relates to organ-specific status and the environment, including infection with H. pylori. Infection with H. pylori is known to be associated with the development of GC. Yokoyama et al. revealed NFATc to be a common cellular target of the two major H. pylori virulence factors, CagA and VacA. Positive or negative deregulation of NFATc may contribute to cellular dysfunctions that underlie the divergent clinical manifestations of H. pylori. 22 No previous reports have shown a direct association between RCAN2 and H. pylori infection. Here, we found that RCAN2 was significantly associated with H. pylori infection ( Table 1) . RCAN2 is a known inhibitor of the calcineurin-NFATc signalling pathway. H. pylori also activates the Wnt-b-catenin signalling pathway in a CagA-dependent manner. 27 H. pylori infection, CagA, the Wnt-b-catenin signalling pathway, NFATc and RCAN2 might all be closely associated with GC tumour growth, but the mechanisms by which altered RCAN2 levels might contribute directly or indirectly to this process are unclear and require further study. In addition, epigenetic aberrations induced by H. pylori might also constitute an early component of gastric carcinogenesis, probably preceding genetic abnormalities. 28 In summary, we revealed that GC expressing RCAN2 was independently associated with a poor prognosis. We also showed that RCAN2 participated in cell invasion and cell proliferation in GC. RCAN2 was colocalised with EGFR, b-catenin, MMP7, laminin-c2 and VEGF expression. In addition, lower levels of phosphorylated AKT and ERK were detected in RCAN2 siRNA-transfected GC cells than in control cells. Thus, RCAN2 plays an important role in GC, and might have potential as a therapeutic target and predictive biomarker for the survival of patients with GC.
